Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

VelaShape III Device in Comparison to Cryolipolysis for Circumferential Reduction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02143960
Recruitment Status : Completed
First Posted : May 21, 2014
Last Update Posted : December 2, 2014
Sponsor:
Information provided by (Responsible Party):
Syneron Medical

Brief Summary:
The purpose of this study is to compare the clinical performance of the VelaShape III device with CoolSculpt for reduction of the waist, love handles and flanks.

Condition or disease Intervention/treatment Phase
Abdominal Fat Device: VelaShape III Device: CoolSculpt Not Applicable

Detailed Description:

VelaShape is a non-invasive (not breaking the skin) device for Body Reshaping and Cellulite Treatment. VelaShape combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation.

The CoolSculpt System is a noninvasive device that reduces fat by freezing fat cells until they break apart.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Clinical Study to Evaluate the Performance of the VelaShape III Device in Comparison to Cryolipolysis for Reduction in Waist / Love Handles / Flanks.
Study Start Date : September 2013
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Arm Intervention/treatment
Active Comparator: Velashape III device
Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation
Device: VelaShape III
Subjects will receive one treatment to their entire waist / love‐handle/ flanks area in a split‐waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
Other Name: Vela

Active Comparator: Noninvasive Cryolipolysis Device
A noninvasive device that reduces fat by freezing fat cells
Device: CoolSculpt
Noninvasive Cryolipolysis
Other Name: Zeltiq




Primary Outcome Measures :
  1. A blinded rating of the treatment area [ Time Frame: 3 month post treatment ]
    Improvement scores of photographs for the treatment side with the VelaShape III device versus the side treated with CoolSculpt will be blindly evaluated by independent reviewer at baseline and at 3 month post treatment time‐point.


Secondary Outcome Measures :
  1. A blinded rating of the treatment area [ Time Frame: 1 week, 1 month and 6 months post treatment ]
    Improvement scores of photographs for the treatment side with the VelaShape III device versus the side treated with CoolSculpt will be blindly evaluated by independent reviewer at baseline and at 1 week, 1 month and 6 months post treatment time‐point.


Other Outcome Measures:
  1. Subject Improvement and Satisfaction Scores [ Time Frame: 1 week, 1 month, 3 month and 6 month post treatment ]
    Subject Improvement and Satisfaction Scores using the Global Aesthetic Improvement (GAI) Scale and Subject Satisfaction Improvement Scale at each follow‐up time point post treatment: 1 week, 1 month, 3 month and 6 month follow‐up visits.

  2. Investigator Improvement and Satisfaction Scores [ Time Frame: 1 week, 1 month, 3 month and 6 month post treatment ]
    Investigator Improvement and Satisfaction Scores using the Global Aesthetic Improvement (GAI) Scale and Subject Satisfaction Improvement Scale at each follow‐up time point post treatment: 1 week, 1 month, 3 month and 6 month follow‐up visits.

  3. Side Effects and Adverse Events [ Time Frame: Study duration ]
    Safety will be evaluated based on the incidence and severity of adverse events caused by the laser treatments



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Informed consent process completed and subject completed consent.
  2. Fitzpatrick Skin Type I to VI
  3. Having excess fat deposits bilaterally in the waist / love‐handle / flank areas.
  4. BMI score is greater than 18.5 and less than 29.9 ‐ normal to overweight, but not obese.
  5. Willing to follow the treatment and follow‐up schedule and post‐treatment care instructions.
  6. Willingness to refrain from a change in diet/ exercise/medication regimen for the entire course of the study.
  7. If female, not pregnant, lactating and must be either post‐menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
  8. Willing to have photographs and images taken of the treated areas to be used de‐identified in evaluations, publications and presentations.

Exclusion Criteria:

  1. Subjects with history of excessive weight fluctuation or expect to gain/lose more than 5 pounds) during the study time frame.
  2. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
  3. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
  4. Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone.
  5. Known photosensitivity.
  6. Having received treatment with laser, RF or other devices in the treated areas within 6 months of treatment or during the study.
  7. Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction.
  8. Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre‐malignant pigmented lesions.
  9. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders.
  10. Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
  11. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
  12. Suffering from hormonal imbalance which may affect weight as per the Investigator's discretion.
  13. History of significant lymphatic drainage problems or impaired circulation in the area to be treated.
  14. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
  15. History of keloid scarring, abnormal wound healing and / or prone to bruising.
  16. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity).
  17. Use of isotretinoin (Accutane®) within 6 months of treatment or during the study.
  18. Allergy to any component of the lotion (VelaSpray Ease) used in this study.
  19. Cryoglobulinemia, Paroxysmal cold hemoglobinuria, or any known sensitivity to cold such as cold urticaria or Raynaud's disease.
  20. Neuropathic disorders such as post‐herpetic neuralgia or diabetic neuropathy, or impaired skin sensation in the area to be treated.
  21. Hernia in the area to be treated.
  22. Participation in a study of another device or drug within 9 month prior to enrollment or during this study, if the treated area was involved.
  23. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02143960


Locations
Layout table for location information
United States, Louisiana
Coleman Center for Cosmetic Dermatologic Surgery
Metairie, Louisiana, United States, 70006
Sponsors and Collaborators
Syneron Medical
Investigators
Layout table for investigator information
Study Director: Shlomit Mann Syneron Medical Ltd.

Layout table for additonal information
Responsible Party: Syneron Medical
ClinicalTrials.gov Identifier: NCT02143960     History of Changes
Other Study ID Numbers: DC85471
First Posted: May 21, 2014    Key Record Dates
Last Update Posted: December 2, 2014
Last Verified: November 2014
Keywords provided by Syneron Medical:
Syneron
Velashape
ELOS
Zeltiq
Cryolipolysis